Radiation damage and radioprotectants: new concepts in the era of molecular medicine
Identifieur interne : 003F60 ( Main/Exploration ); précédent : 003F59; suivant : 003F61Radiation damage and radioprotectants: new concepts in the era of molecular medicine
Auteurs : M I KoukourakisSource :
- The British Journal of Radiology [ 0007-1285 ] ; 2012.
Abstract
Exposure to ionising radiation results in mutagenesis and cell death, and the clinical manifestations depend on the dose and the involved body area. Reducing carcinogenesis in patients treated with radiotherapy, exposed to diagnostic radiation or who are in certain professional groups is mandatory. The prevention or treatment of early and late radiotherapy effects would improve quality of life and increase cancer curability by intensifying therapies. Experimental and clinical data have given rise to new concepts and a large pool of chemical and molecular agents that could be effective in the protection and treatment of radiation damage. To date, amifostine is the only drug recommended as an effective radioprotectant. This review identifies five distinct types of radiation damage (I, cellular depletion; II, reactive gene activation; III, tissue disorganisation; IV, stochastic effects; V, bystander effects) and classifies the radioprotective agents into five relevant categories (A, protectants against all types of radiation effects; B, death pathway modulators; C, blockers of inflammation, chemotaxis and autocrine/paracrine pathways; D, antimutagenic keepers of genomic integrity; E, agents that block bystander effects). The necessity of establishing and funding central committees that guide systematic clinical research into evaluating the novel agents revealed in the era of molecular medicine is stressed.
Url:
DOI: 10.1259/bjr/16386034
PubMed: 22294702
PubMed Central: 3486665
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 004773
- to stream Pmc, to step Curation: 004772
- to stream Pmc, to step Checkpoint: 002773
- to stream Ncbi, to step Merge: 004A34
- to stream Ncbi, to step Curation: 004A34
- to stream Ncbi, to step Checkpoint: 004A34
- to stream Main, to step Merge: 003F74
- to stream Main, to step Curation: 003F60
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Radiation damage and radioprotectants: new concepts in the era of molecular medicine</title>
<author><name sortKey="Koukourakis, M I" sort="Koukourakis, M I" uniqKey="Koukourakis M" first="M I" last="Koukourakis">M I Koukourakis</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">22294702</idno>
<idno type="pmc">3486665</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3486665</idno>
<idno type="RBID">PMC:3486665</idno>
<idno type="doi">10.1259/bjr/16386034</idno>
<date when="2012">2012</date>
<idno type="wicri:Area/Pmc/Corpus">004773</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">004773</idno>
<idno type="wicri:Area/Pmc/Curation">004772</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">004772</idno>
<idno type="wicri:Area/Pmc/Checkpoint">002773</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">002773</idno>
<idno type="wicri:Area/Ncbi/Merge">004A34</idno>
<idno type="wicri:Area/Ncbi/Curation">004A34</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">004A34</idno>
<idno type="wicri:doubleKey">0007-1285:2012:Koukourakis M:radiation:damage:and</idno>
<idno type="wicri:Area/Main/Merge">003F74</idno>
<idno type="wicri:Area/Main/Curation">003F60</idno>
<idno type="wicri:Area/Main/Exploration">003F60</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Radiation damage and radioprotectants: new concepts in the era of molecular medicine</title>
<author><name sortKey="Koukourakis, M I" sort="Koukourakis, M I" uniqKey="Koukourakis M" first="M I" last="Koukourakis">M I Koukourakis</name>
</author>
</analytic>
<series><title level="j">The British Journal of Radiology</title>
<idno type="ISSN">0007-1285</idno>
<idno type="eISSN">1748-880X</idno>
<imprint><date when="2012">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p>Exposure to ionising radiation results in mutagenesis and cell death, and the clinical manifestations depend on the dose and the involved body area. Reducing carcinogenesis in patients treated with radiotherapy, exposed to diagnostic radiation or who are in certain professional groups is mandatory. The prevention or treatment of early and late radiotherapy effects would improve quality of life and increase cancer curability by intensifying therapies. Experimental and clinical data have given rise to new concepts and a large pool of chemical and molecular agents that could be effective in the protection and treatment of radiation damage. To date, amifostine is the only drug recommended as an effective radioprotectant. This review identifies five distinct types of radiation damage (I, cellular depletion; II, reactive gene activation; III, tissue disorganisation; IV, stochastic effects; V, bystander effects) and classifies the radioprotective agents into five relevant categories (A, protectants against all types of radiation effects; B, death pathway modulators; C, blockers of inflammation, chemotaxis and autocrine/paracrine pathways; D, antimutagenic keepers of genomic integrity; E, agents that block bystander effects). The necessity of establishing and funding central committees that guide systematic clinical research into evaluating the novel agents revealed in the era of molecular medicine is stressed.</p>
</div>
</front>
</TEI>
<affiliations><list></list>
<tree><noCountry><name sortKey="Koukourakis, M I" sort="Koukourakis, M I" uniqKey="Koukourakis M" first="M I" last="Koukourakis">M I Koukourakis</name>
</noCountry>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003F60 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003F60 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= Main |étape= Exploration |type= RBID |clé= PMC:3486665 |texte= Radiation damage and radioprotectants: new concepts in the era of molecular medicine }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:22294702" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a LymphedemaV1
![]() | This area was generated with Dilib version V0.6.31. | ![]() |